Vermillion to Present at the 2015 Achieving Optimal Health Conference in Conjunction with Company's Women's Outreach Programs
AUSTIN, Texas, Oct. 15, 2015 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced that it will present at the 2015 Achieving Optimal Health Conference (AOHC) in Washington, DC on October 24th. Valerie Palmieri, President and Chief Executive Officer of Vermillion, will speak on the "non-silent" symptoms associated with benign and malignant pelvic masses and how women may achieve better medical care through the use of modern diagnostic techniques, such as Vermillion's OVA1® test.
"We're delighted to join with AOHC to increase awareness on proactively managing pelvic health to a wider audience," said Ms. Palmieri. "As we have previously stated, our primary goal is to lead with education, increase awareness and allow women to control their destiny and understand their pelvic mass disease, a disease which impacts 20 million patients on an-going basis in the US alone. Our outreach program has already begun, through our relationships with ovarian cancer and hereditary cancer advocacy groups, as well as our personalized ovarian cancer quiz located on our website at www.vermillion.com and our ASPiRA LABS Facebook page and Twitter account."
About the Achieving Optimal Health Conference (AOHC)
Founded by Doro Bush Koch, Patricia Reilly Koch, Therese Burch and Patrice King Brickman, the 2015 AOHC is a conference dedicated to helping people reach optimal health by connecting them with the resources needed to learn how to nourish their bodies and minds. Attendees learn the importance of taking responsibility for their preventive healthcare measures. Presenters at the conference include leaders from Aetna, Inc., the Cleveland Clinic and Georgetown University. For more information, go to http://achievingoptimalhealthconference.com/.
About Vermillion
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in gynecologic disease. The company's lead diagnostic, OVA1, is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using an innovative algorithmic approach. As the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, OVA1 represents a new class of software-based diagnostics. For additional information, including published clinical trials, visit www.vermillion.com.
About OVA1
- OVA1 is a proprietary FDA-cleared blood test to help physicians assess the risk of ovarian cancer prior to surgery and trigger the involvement of a specialist (gynecologic oncologist) for higher risk patients
- The OvaCalc® proprietary algorithm combines five biomarker results into a single numerical "risk score" that stratifies patients into "higher risk" and "lower risk" when combined with clinical assessment
- In two pivotal clinical trials, OVA1 plus clinical impression detected 96% of all malignancies vs. 75% for clinical impression alone. It subsequently reduced the number of malignancies missed from 25% to 4%, a reduction of 83%
- For early-stage cancers specifically, 31% were missed by clinical impression alone. This was reduced to 5% when OVA1 was added to clinical impression, a reduction of 85%
- Vermillion is currently developing a next-generation test, OVA2, which has an expected release in the second half of 2015, subject to FDA clearance
Investor Relations Contact:
Michael Wood
LifeSci Advisors LLC
Tel 1-646-597-6983
[email protected]
SOURCE Vermillion, Inc.
Share this article